1. Search Result
Search Result
Results for "

FGFR2

" in MedChemExpress (MCE) Product Catalog:

83

Inhibitors & Agonists

4

Inhibitory Antibodies

7

Natural
Products

21

Recombinant Proteins

4

Isotope-Labeled Compounds

2

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145231

    FGFR Cancer
    FGFR2-IN-2 (Compound 38) is a selective FGFR2 inhibitor with IC50s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively .
    FGFR2-IN-2
  • HY-162865

    FGFR Cancer
    FGFR2-IN-3 is an inhibitor of fibroblast growth factor receptor 2 (FGFR2). FGFR2-IN-3 has good binding properties, forming key interactions and inducing conformational changes in FGFR2. FGFR2-IN-3 can be used for research on tumors .
    FGFR2-IN-3
  • HY-145230

    FGFR Others
    FGFR2-IN-1 is a selective FGFR2 inhibitor with an IC50 of 140 nM.
    FGFR2-IN-1
  • HY-162626

    PROTACs FGFR Cancer
    FGFR2 degrader 1 (compound 28E) is a selectively PROTACS degrader of FGFR2, with the DC50 of 0.645 nM. FGFR2 plays an important role in cancer research (Pink: ligand of target protein; (HY-13304) black: linker; blue: ligand of E3 ligase) .
    FGFR2 degrader 1
  • HY-RS04915

    Small Interfering RNA (siRNA) FGFR Others

    FGFR2 Human Pre-designed siRNA Set A contains three designed siRNAs for FGFR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    FGFR2 Human Pre-designed siRNA Set A
    FGFR2 Human Pre-designed siRNA Set A
  • HY-RS04916

    Small Interfering RNA (siRNA) Others

    Fgfr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Fgfr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Fgfr2 Mouse Pre-designed siRNA Set A
    Fgfr2 Mouse Pre-designed siRNA Set A
  • HY-RS04917

    Small Interfering RNA (siRNA) Others

    Fgfr2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Fgfr2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Fgfr2 Rat Pre-designed siRNA Set A
    Fgfr2 Rat Pre-designed siRNA Set A
  • HY-151903S

    FGFR Cancer
    FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC50s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC50s of 2.7 nM and 6.1 nM, respectively .
    FGFR2/3-IN-1
  • HY-170919

    FGFR Cancer
    FGFR2/3-IN-2 (compound 10) is an orally active FGFR2 and FGFR3 inhibitor. FGFR2/3-IN-2 inhibits FGFR2 and FGFR3 with IC50s of 3.7 nM and 31.2 nM (preincubation time 1 h), respectively. FGFR2/3-IN-2 spares FGFR1/4 and other kinases without causing diarrhea and serum phosphate elevation in vivo. FGFR2/3-IN-2 induces tumor stasis or regression in the SNU-16 gastric cancer model .
    FGFR2/3-IN-2
  • HY-163985

    PROTACs FGFR Apoptosis Cancer
    PROTAC FGFR2 degrader 1 (compound N5) is a PROTAC that effectively targets FGFR2 with DC50 of 6.46 nM, the FGFR2 IC50 is 0.08 nM. PROTAC FGFR2 degrader 1 has anti-proliferative activity and highly selective, induces G0/G1 arrest of KATOIII and SNU16 cell cycle and inhibits apoptosis by reducing the activation of p-ERK and p-PLCγ, the downstream proteins of FGFR2. PROTAC FGFR2 degrader 1 inhibits gastric cancer cells remained above 50% at a concentration of 0.17 nM. PROTAC FGFR2 degrader 1 potently inhibits the growth of SNU16 xenograft tumors in mouse model (Structure Note: Pink, FGFR2 activator: HY-18708; Blue, E3 ligase ligand: HY--10984; Black, linker: HY-163989; E3 ligase ligand + linker:HY-163986) .
    PROTAC FGFR2 degrader 1
  • HY-P99007

    BAY 1179470

    FGFR Cancer
    Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research .
    Aprutumab
  • HY-141600

    BAY 1187982

    Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis Cancer
    Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer [2].
    Aprutumab ixadotin
  • HY-N0183
    Formononetin
    10+ Cited Publications

    Biochanin B; Flavosil; Formononetol

    FGFR Apoptosis Cardiovascular Disease Cancer
    Formononetin is a potent FGFR2 inhibitor with an IC50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth .
    Formononetin
  • HY-101544

    FGFR Cancer
    ARQ 069, an analog of ARQ 523, inhibits FGFR in an enantiospecific manner. ARQ 069 targets the unphosphorylated, inactive forms of FGFR1/FGFR2 kinases (IC50s of 0.84 μM and 1.23 μM, respectively). ARQ 069 inhibits FGFR1/FGFR2 autophosphorylation (IC50s of 2.8 and 1.9 μM, respectively) through a mechanism in a non-ATP competitive dependent manner .
    ARQ 069
  • HY-163620

    FGFR Apoptosis Cancer
    LHQ490 is a selective FGFR2 inhibitor, with an IC50 of 5.2 nM. LHQ490 efficiently inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 1.4 nM. LHQ490 inhibits FGFR2-driven cancer cell proliferation and induces apoptosis of FGFR2-driven cancer cells .
    LHQ490
  • HY-117595

    FAK FGFR Apoptosis Cancer
    PHM16 is an ATP competitive inhibitor of FAK and FGFR2 (IC50: 0.4 μM and 0.37 μM, respectively), with direct potent anti-angiogenic activity .
    PHM16
  • HY-170934

    FGFR Cancer
    BW710 is an orally active fibroblast growth factor receptor 2 (FGFR2) inhibitor. BW710 inhibits the proliferation of BaF3-FGFR2 cells with an IC50 of 2.8 nM. BW710 abolishes FGFR2 enzymatic activity and is selective against other 75 tyrosine kinases including FGFR1, FGFR3, and FGFR4 at 1 μM. BW710 suppresses the FGFR2 signaling and selectively inhibits FGFR2-driven cancer cell proliferation. BW710 displays reasonable pharmacokinetic properties with an oral bioavailability of 29 % in mice .
    BW710
  • HY-N0183R

    FGFR Apoptosis Cardiovascular Disease Cancer
    Formononetin (Standard) is the analytical standard of Formononetin. This product is intended for research and analytical applications. Formononetin is a potent FGFR2 inhibitor with an IC50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth .
    Formononetin (Standard)
  • HY-149843

    FGFR PROTACs Cancer
    LC-MB12 is an orally active PROTAC compound targets FGFR2 degradation with a DC50 of 11.8 nM. LC-MB12 contains BGJ398 (a FGFR2 inhibitor), PROTAC linker and CRBN.LC-MB12 inhibits FGFR2 signaling in gastric cancer cells and has anti-tumor activity .
    LC-MB12
  • HY-172923

    FGFR Cancer
    Glu-IN-1 (compound AF1) is a covalent and selective FGFR2 inhibitor with an IC50 of 1.6 μM. Glu-IN-1 covalently modifies Glu489 in FGFR2 .
    FGFR-IN-20
  • HY-147250A

    RLY-4008 hydrochloride

    FGFR Cancer
    Lirafugratinib (RLY-4008) hydrochloride is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib hydrochloride covalently binds to Cys491. Lirafugratinib hydrochloride targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .
    Lirafugratinib hydrochloride
  • HY-147250

    RLY-4008

    FGFR Cancer
    Lirafugratinib (RLY-4008) is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib covalently binds to Cys491. Lirafugratinib targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .
    Lirafugratinib
  • HY-123134

    FGFR Cancer
    FIIN-4 is a first-in-class, orally active and covalent FGFR inhibitor with IC50s of 2.6 nM, 2.6 nM, 5.6 nM, 9.2 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FIIN-4 can inhibit metastatic tumor growth.
    FIIN-4
  • HY-172921

    FGFR Cancer
    FGFR-IN-18 (Compound KF7) is a lysine-targeting FGFR covalent inhibitor, with IC50s of: 1.1 nM for FGFR2, 1.3 nM for FGFR1, 31.5 nM for FGFR4. FGFR-IN-18 also has affinity for FGFR3 (inhibition rate of 52% at 10 nM). FGFR-IN-18 covalently modifies Lys485 (an reactive site of FGFRs) .
    FGFR-IN-18
  • HY-163989

    PROTAC Linkers Cancer
    N-Ethylheptanamide is a PROTAC linker. N-Ethylheptanamide can be used in synthesis PROTAC FGFR2 degrader 1 (HY-163985) .
    N-Ethylheptanamide
  • HY-17601
    Alofanib
    4 Publications Verification

    RPT835

    FGFR Apoptosis Cardiovascular Disease Cancer
    Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Anticancer and antiangiogenic activity [2].
    Alofanib
  • HY-172916

    SHP2 FGFR p38 MAPK ERK Cancer
    LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR (IC50 values are 71.6 and 8.9 nM, respectively). LC-SF-14 inhibits FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation. LC-SF-14 inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). LC-SF-14 has antitumor activity in the SNU-16 xenograft mouse model. LC-SF-14 can be used in FGFR2-driven gastric cancer research .
    LC-SF-14
  • HY-18602

    FGFR Cancer
    FIIN-2 is an irreversible inhibitor of FGFR with an IC50 of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
    FIIN-2
  • HY-145043

    FGFR Cancer
    FGFR-IN-1 is a potent FGFR inhibitor with an IC50 of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219) .
    FGFR-IN-1
  • HY-N0060
    Ferulic acid
    5+ Cited Publications

    Coniferic acid

    FGFR Endogenous Metabolite Cancer
    Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.
    Ferulic acid
  • HY-N0060A
    Ferulic acid sodium
    5+ Cited Publications

    Coniferic acid sodium

    FGFR Endogenous Metabolite Reactive Oxygen Species Cardiovascular Disease Cancer
    Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.
    Ferulic acid sodium
  • HY-18603

    EGFR FGFR Cancer
    FIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
    FIIN-3
  • HY-162577

    FGFR Cancer
    FGFR-IN-14 (compound 10h) is a pan-FGFR inhibitor. FGFR-IN-14 inhibits FGFR1, FGFR2, FGFR3 and FGFR2 V564F gatekeeper mutant with IC50s of 46, 41, 99, and 62 nM, respectively. FGFR-IN-14 strongly suppresses NCI-H520 lung cancer cells, SNU-16 and KATO III gastric cancer cells proliferation with IC50s of 19, 59, and 73 nM, respectively .
    FGFR-IN-14
  • HY-13304
    LY2874455
    3 Publications Verification

    FGFR Cancer
    LY2874455 is a pan-FGFR inhibitor with IC50s of 2.8, 2.6, 6.4, 6 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.
    LY2874455
  • HY-101466

    FGFR Cancer
    E7090 is an orally available, potent, and selective FGFR inhibitor with IC50s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4, respectively .
    E7090
  • HY-19957
    Zoligratinib
    3 Publications Verification

    Debio 1347; CH5183284

    FGFR Cancer
    Zoligratinib (Debio 1347) is an orally available and selective FGFR inhibitor with IC50s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
    Zoligratinib
  • HY-156632

    KIN-3248

    FGFR Cancer
    Resigratinib (KIN-3248) is an irreversible and orally active covalent inhibitor of FGFR1-4 that effectively inhibits wild-type and drug-resistant mutations (such as FGFR2 V565F, FGFR3 V555M). Resigratinib covalently binds to the Cys492 site of FGFR, blocks the FGFR signaling pathway, inhibits tumor cell proliferation and induces apoptosis. Resigratinib can be used for the study of FGFR2/3-driven solid tumors (such as cholangiocarcinoma and bladder cancer) [2].
    Resigratinib
  • HY-100818
    Futibatinib
    3 Publications Verification

    TAS-120

    FGFR Cancer
    Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) [2] .
    Futibatinib
  • HY-13330
    Fexagratinib
    25+ Cited Publications

    AZD4547; ADSK091

    FGFR Cancer
    Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the FGFR family with IC50s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
    Fexagratinib
  • HY-13311A
    Infigratinib phosphate
    Maximum Cited Publications
    33 Publications Verification

    BGJ-398 phosphate; NVP-BGJ398 phosphate

    FGFR Cancer
    Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
    Infigratinib phosphate
  • HY-13034
    Gandotinib
    3 Publications Verification

    LY2784544

    JAK FLT3 FGFR VEGFR Cancer
    Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC50 of 4, 25, 32, 44, and 95 nM.
    Gandotinib
  • HY-13311S

    BGJ-398-d3; NVP-BGJ398-d3

    FGFR Cancer
    Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the FGFR family, with IC50 values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively .
    Infigratinib-d3
  • HY-13311
    Infigratinib
    Maximum Cited Publications
    33 Publications Verification

    BGJ-398; NVP-BGJ398

    FGFR Apoptosis Cancer
    Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC50s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
    Infigratinib
  • HY-168286

    FGFR Cancer
    FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, with the IC50s of 8 nM, 4 nM and 3.8 nM, respectively. FGFR-IN-16 plays an important role in cancer research 1].
    FGFR-IN-16
  • HY-150652

    FGFR Apoptosis Cancer
    FGFR-IN-8 (Compound 17a) is a highly potent and orally active panFGFR inhibitor against wild-type and mutant FGFRs. FGFR-IN-8 shows inhibition with IC50 values of <0.5, 189.1, <0.5, 22.6, <0.5 and 7.30 nM against FGFR1, V564F-FGFR2, N549H-FGFR2, V555M-FGFR3, FGFR3 and FGFR4, respectively. GFR-IN-8 induces cancer cell apoptosis and shows anticancer activities .
    FGFR-IN-8
  • HY-100818R

    TAS-120 (Standard)

    Reference Standards FGFR Cancer
    Futibatinib (Standard) is the analytical standard of Futibatinib. This product is intended for research and analytical applications. Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) [2] .
    Futibatinib (Standard)
  • HY-148779

    FGFR Cancer
    FGFR3-IN-5 is a potent and selective FGFR3 inhibitor with IC50 values of 3, 44, and 289 nM for FGFR3, FGFR2, and FGFR1, respectively. FGFR3-IN-5 can be used in research of cancer .
    FGFR3-IN-5
  • HY-N0060S1

    Isotope-Labeled Compounds FGFR Endogenous Metabolite Cancer
    Ferulic acid- 13C3 is the 13C-labeled Ferulic acid. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.
    Ferulic acid-13C3
  • HY-109099
    Pemigatinib
    10+ Cited Publications

    INCB054828

    FGFR Cancer
    Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma [2].
    Pemigatinib
  • HY-N0060R

    FGFR Endogenous Metabolite Cancer
    Ferulic acid (Standard) is the analytical standard of Ferulic acid. This product is intended for research and analytical applications. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.
    Ferulic acid (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: